BioSpace News Archive

HiberCell announced a clinical trial collaboration with Merck, known as MSD outside of the United States and Canada.

Today the American Academy of Physical Medicine and Rehabilitation (AAPM&R) released the next two parts in a series of consensus statements with practical guidance for clinicians treating patients suffering from breathing discomfort or cognitive symptoms, two common symptoms of Post-Acute Sequelae of SARS-CoV-2 infection (PASC), or Long COVID.

Oravax’s oral vaccine targets three surface proteins, making it potentially more effective against current and future variants.

Cartesian Therapeutics today announced the appointment of five internationally recognized Senior Advisors to support its growing clinical pipeline for autoimmune, respiratory, and inflammatory diseases.

Actinium Pharmaceuticals, Inc. today announced that updated data from the recently complete Actimab-A and CLAG-M Phase 1 combination trial being conducted at the Medical College of Wisconsin (MCW) was presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH) that is being held December 11 – 14, 2021 in Atlanta, Georgia and virtually.

Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient with hepatocellular carcinoma (HCC) has been dosed with MIV-818 in a phase 1b /2a combination study with the company’s candidate drug MIV-818.

AnHeart Therapeutics today announced the completion of a $61 million oversubscribed Series B financing round led by new investor Octagon Capital, with participation from Innovent Biologics, Cenova, Laurion Capital, and Sage Partners.

ARTMS Inc. is pleased to announce the production of zirconium-89 oxalate using a low energy medical cyclotron in a US based commercial nuclear pharmacy.

Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced clinical study results using the Cellworks Biosimulation Platform and Computational Omics Biology Model (CBM) to predict therapy response for individual Mantle Cell Lymphoma (MCL) patients were featured in a poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition

AML Biomarker Identification Can Improve Clinical Trials for New Drugs and Accelerate Drug Approvals.